HAMBURG, Germany, Sept. 14 /PRNewswire/ -- Indivumed announces today that a service agreement with Roche Diagnostics GmbH was signed. Within this agreement Indivumed will apply its automated immunohistochemistry service platform for analyzing various biomarkers and drug targets in the area of oncology. Indivumed will provide for this project a selection of tumor tissue sections from its tumor biobank as well as specifically collected clinical samples. The analysis of specific biomarkers and drug targets should enable Roche to efficiently develop novel targeted therapies for cancer.
Indivumed is a privately held biotech company focused on the generation, characterization and analysis of highly standardized biological samples from human cancer. Founded in 2002 and headquartered in Hamburg, Germany with a subsidiary in Kensington, Maryland, USA, Indivumed has cooperation agreements with all major oncological hospitals in the Hamburg metropolitan area. Indivumed's current tumor biobank of over 6500 patient-cases, collected with a mean cold ischemia time of less than eight minutes, serves as a resource for Indivumed's internal cancer research in biomarkers and primary cell drug screening as well as for the use of pharmaceutical and biopharma partners through tumor biobank access and IHC services.
Indivumed, Inc.CONTACT: Hartmut Juhl MD PhD, CEO of Indivumed GmbH, T: +49-40-413383-10,F: +49-40-413383-14, juhl@indivumed.com, or Kevin Sullivan, Director,Marketing and Sales of Indivumed, Inc., +1-301-588-4650,sullivan@indivumed.com
Web site: http://www.indivumed.com/
